White Pine Capital LLC acquired a new stake in Abbott Laboratories (NYSE:ABT – Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 26,598 shares of the healthcare product maker’s stock, valued at approximately $2,629,000.
Several other large investors have also recently made changes to their positions in the business. Bank of America Corp DE bought a new stake in shares of Abbott Laboratories during the 2nd quarter worth $1,603,607,000. Legal & General Group Plc purchased a new position in shares of Abbott Laboratories in the 2nd quarter worth about $1,082,524,000. Flossbach Von Storch SE bought a new position in Abbott Laboratories during the second quarter valued at about $902,938,000. Jupiter Topco LLC bought a new position in Abbott Laboratories during the second quarter valued at about $732,788,000. Finally, BlackRock Inc. increased its holdings in Abbott Laboratories by 4.6% during the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after buying an additional 6,769,518 shares during the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several analysts have commented on ABT shares. Royal Bank Of Canada lowered their price objective on shares of Abbott Laboratories from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Thursday, October 22nd. Robert W. Baird increased their target price on shares of Abbott Laboratories from $121.00 to $123.00 and gave the company an “outperform” rating in a research report on Thursday, October 22nd. Argus lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, October 27th. UBS Group lowered their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Finally, Weiss Ratings upgraded Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, September 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $118.32.
Read Our Latest Research Report on ABT
Abbott Laboratories Stock Performance
NYSE ABT opened at $108.59 on Monday. The firm has a market cap of $188.08 billion, a P/E ratio of 40.52, a price-to-earnings-growth ratio of 1.90 and a beta of 0.54. The company has a quick ratio of 1.00, a current ratio of 1.45 and a debt-to-equity ratio of 0.57. The company’s 50 day moving average is $103.93 and its 200-day moving average is $101.74. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $132.02.
Abbott Laboratories (NYSE:ABT – Get Free Report) last released its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, hitting the consensus estimate of $1.42. Abbott Laboratories had a net margin of 9.75% and a return on equity of 18.04%. The company had revenue of $13.01 billion during the quarter, compared to the consensus estimate of $12.99 billion. During the same period last year, the firm earned $1.30 EPS. Abbott Laboratories’s revenue for the quarter was up 14.5% on a year-over-year basis. Sell-side analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current year.
Abbott Laboratories Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a dividend of $0.63 per share. The ex-dividend date is Thursday, October 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is currently 94.03%.
Insider Activity at Abbott Laboratories
In other news, EVP Mary Moreland sold 3,500 shares of the firm’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $116.00, for a total value of $406,000.00. Following the completion of the transaction, the executive vice president directly owned 100,791 shares of the company’s stock, valued at $11,691,756. This trade represents a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.46% of the stock is owned by insiders.
About Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.
Featured Articles
- Five stocks we like better than Abbott Laboratories
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
